Long-term study of XXXX in the treatment of @entity302 .

@entity1 @entity410 @entity390 @entity5305 @entity391 @entity302 @entity3148
The purpose of this study was to investigate the long-term efficacy and tolerability of @entity5305 (GVG) in the treatment of @entity302 . 36 @entity1 with severe therapy resistant @entity302 participated, the majority exhibiting complex partial @entity410 . The mean follow-up period was 9.3 months. GVG was administered as add-on therapy, to keep serum levels of concomitant treatment constant. The mean dose of GVG was 2.6 g's per day. Fifty-six per cent of the @entity1 , including three @entity1 with juvenile @entity3148 , experienced more than a 50% reduction in @entity410 frequency. No signs of tolerance development to the antiepileptic effect of GVG was demonstrated. Two @entity1 were withdrawn from GVG treatment due to increased @entity410 frequency, and two due to side effects in the form of @entity391 and @entity390 . Incidentally, the side effects observed were harmless and transient. Fifty per cent of the @entity1 experienced no side effects at all. GVG seems to be a valuable antiepileptic compound. The results of this long-term study confirm observations from several short controlled trials.
